DEERFIELD, Ill. / Sep 19, 2023 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2023 financial results on Thursday, November 2, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information.
This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter’s permission.
About Baxter
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
Last Trade: | US$22.93 |
Daily Change: | 0.18 0.79 |
Daily Volume: | 876,926 |
Market Cap: | US$11.770B |
September 16, 2025 July 31, 2025 July 07, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load